Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adicon HoldingsADCNF 75 Debt-to-EBITDA is 6.38 as of Dec. 2025, which is 314% above its 10-year median of 1.54. GuruFocus rates ADCNF with a GF Score™ of 75/100 and a GF Value™ of $1.40. The stock has 6 warning signs investors should review. Among 112 Medical Diagnostics & Research companies, Adicon Holdings ranks worse than 87.5% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Adicon Holdings's Debt-to-EBITDA or its related term are showing as below:
ADCNF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.56 Med: 1.54 Max: 5.82
Current: 5.82
During the past 6 years, the highest Debt-to-EBITDA Ratio of Adicon Holdings was 5.82. The lowest was 0.56. And the median was 1.54.
ADCNF's Debt-to-EBITDA is ranked worse than 87.5% of 112
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.31
vs ADCNF: 5.82
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Adicon Holdings Debt-to-EBITDA Related Terms
Adicon Holdings Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Adicon Holdings's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADCNF vs TMO, DHR, IDXX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Adicon Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adicon Holdings Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Adicon Holdings's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Adicon Holdings's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Adicon Holdings (ADCNF) has a Debt-to-EBITDA of 6.38 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Adicon Holdings. This is 314% above median its historical median of 1.54. Over the past decade, Adicon Holdings' Debt-to-EBITDA has ranged from 0.56 to 5.82. According to the industry distribution chart, Adicon Holdings ranks #98 out of 112 companies in the Medical Diagnostics & Research industry, placing it in the top 87.5%.
Is Adicon Holdings' Debt-to-EBITDA too high?
Adicon Holdings' current Debt-to-EBITDA of 6.38 is 314% above median its 10-year median of 1.54. Over the past 10 years, this metric has ranged from a low of 0.56 to a high of 5.82. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.31. Adicon Holdings' value of 6.38 is 176.2% above this industry median. Based on the distribution chart, Adicon Holdings ranks #98 out of 112 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Adicon Holdings has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Adicon Holdings' Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Adicon Holdings ranks #98 out of 112 companies for Debt-to-EBITDA. This places Adicon Holdings in the lower half of its industry. The industry median Debt-to-EBITDA is 2.31. Adicon Holdings' value of 6.38 is 176.2% above this benchmark. Historically, Adicon Holdings' own Debt-to-EBITDA has ranged from 0.56 to 5.82 over the past decade. While the company's 10-year median is 1.54 vs. the industry median of 2.31, Adicon Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.31, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adicon Holdings's current Debt-to-EBITDA of 6.38 is 176.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Adicon Holdings. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adicon Holdings's current Debt-to-EBITDA is 6.38, which is 314% above median its own 10-year median of 1.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicon Holdings stock overvalued right now?
Adicon Holdings (ADCNF) has a current Debt-to-EBITDA of 6.38. The stock's GF Value™ is $1.40, compared to a current price of $0.65 — trading 53.6% below its estimated fair value. The current Debt-to-EBITDA is 6.38, which is 314% above median its 10-year median of 1.54 and 176.2% above the Medical Diagnostics & Research industry median of 2.31. Adicon Holdings' overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Adicon Holdings (ADCNF), the current Debt-to-EBITDA is 6.38 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adicon Holdings (ADCNF) Overvalued in 2026?
Based on GuruFocus' analysis, Adicon Holdings stock appears to be undervalued.
The current stock price of $0.65 is trading 53.6% below its estimated GF Value™ of $1.40.
Key valuation signals for ADCNF:
Debt-to-EBITDA: 6.38 (314% above median its 10-year median of 1.54)
GF Value™: $1.40 vs. price of $0.65 (53.6% below fair value)
Industry Position: 176.2% above the Medical Diagnostics & Research median (#98 of 112)
No single metric tells the full story. See the ADCNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adicon Holdings Ltd is a ICL service provider in China. It offers comprehensive testing services to hospitals and health check centers through an integrated network of self-operated laboratories across China. Its testing services platform includes clinical laboratories, pathology laboratories, reproductive genetics laboratories, gene laboratories, and mass spectrometry laboratories, consisting of over 4,000 medical diagnostic tests, the introduction of over 300 new high-end diagnostic tests.
75GF Score
Get the complete analysis for ADCNF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADCNF has been successfully added to your 
